Stereotyped B-cell receptors in chronic lymphocytic leukemia

Andreas Agathangelidis, Anna Vardi, Panagiotis Baliakas, Kostas Stamatopoulos

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Over the last decade, immunogenetic analysis of B-cell receptor immunoglobulins (BcR IGs) has proved to be a particularly fruitful field in chronic lymphocytic leukemia (CLL), not only for understanding disease pathogenesis but also for discriminating clinical subgroups with markedly distinct course and outcome. Of utmost importance was the identification of quasi-identical BcR IGs among unrelated patients with CLL, fittingly coined as "stereotypy," that set the wheels in motion for unraveling the role of antigen(s) in the selection and expansion of the leukemic clones. The categorization of CLL clones into "subsets" according to shared BcR IG structural characteristics provided a compartmentalized view of this otherwise heterogeneous disease, which eventually led to defining strikingly homogeneous groups of patients in terms of: (i) functional properties of the clonal BcR IGs, e.g. BcR reactivity and signaling; (ii) clonal genetic landscape, e.g. genomic aberrations, gene expression/methylation profiles, microRNA signatures; and (iii) clinical course and outcome. The remarkable restriction of the CLL IG gene repertoire, resulting to a great degree from the high impact of BcR IG stereotypy, may also prompt speculations regarding CLL ontogenesis. Overall, the BcR IG molecule justifiably lies at the heart of CLL clinical research, holding the promise of subset-tailored therapies.

Original languageEnglish
Pages (from-to)2252-2261
Number of pages10
JournalLeukemia and Lymphoma
Volume55
Issue number10
DOIs
Publication statusPublished - Oct 1 2014

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Immunoglobulins
B-Lymphocytes
Clone Cells
Immunogenetics
MicroRNAs
Transcriptome
Methylation
Antigens
Research
Genes

Keywords

  • B-cell receptors
  • BcR IG
  • Chronic lymphocytic leukemia

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

Stereotyped B-cell receptors in chronic lymphocytic leukemia. / Agathangelidis, Andreas; Vardi, Anna; Baliakas, Panagiotis; Stamatopoulos, Kostas.

In: Leukemia and Lymphoma, Vol. 55, No. 10, 01.10.2014, p. 2252-2261.

Research output: Contribution to journalArticle

Agathangelidis, Andreas ; Vardi, Anna ; Baliakas, Panagiotis ; Stamatopoulos, Kostas. / Stereotyped B-cell receptors in chronic lymphocytic leukemia. In: Leukemia and Lymphoma. 2014 ; Vol. 55, No. 10. pp. 2252-2261.
@article{5bcc101e36944794b792fe4b8c6fe7f1,
title = "Stereotyped B-cell receptors in chronic lymphocytic leukemia",
abstract = "Over the last decade, immunogenetic analysis of B-cell receptor immunoglobulins (BcR IGs) has proved to be a particularly fruitful field in chronic lymphocytic leukemia (CLL), not only for understanding disease pathogenesis but also for discriminating clinical subgroups with markedly distinct course and outcome. Of utmost importance was the identification of quasi-identical BcR IGs among unrelated patients with CLL, fittingly coined as {"}stereotypy,{"} that set the wheels in motion for unraveling the role of antigen(s) in the selection and expansion of the leukemic clones. The categorization of CLL clones into {"}subsets{"} according to shared BcR IG structural characteristics provided a compartmentalized view of this otherwise heterogeneous disease, which eventually led to defining strikingly homogeneous groups of patients in terms of: (i) functional properties of the clonal BcR IGs, e.g. BcR reactivity and signaling; (ii) clonal genetic landscape, e.g. genomic aberrations, gene expression/methylation profiles, microRNA signatures; and (iii) clinical course and outcome. The remarkable restriction of the CLL IG gene repertoire, resulting to a great degree from the high impact of BcR IG stereotypy, may also prompt speculations regarding CLL ontogenesis. Overall, the BcR IG molecule justifiably lies at the heart of CLL clinical research, holding the promise of subset-tailored therapies.",
keywords = "B-cell receptors, BcR IG, Chronic lymphocytic leukemia",
author = "Andreas Agathangelidis and Anna Vardi and Panagiotis Baliakas and Kostas Stamatopoulos",
year = "2014",
month = "10",
day = "1",
doi = "10.3109/10428194.2013.879715",
language = "English",
volume = "55",
pages = "2252--2261",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "10",

}

TY - JOUR

T1 - Stereotyped B-cell receptors in chronic lymphocytic leukemia

AU - Agathangelidis, Andreas

AU - Vardi, Anna

AU - Baliakas, Panagiotis

AU - Stamatopoulos, Kostas

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Over the last decade, immunogenetic analysis of B-cell receptor immunoglobulins (BcR IGs) has proved to be a particularly fruitful field in chronic lymphocytic leukemia (CLL), not only for understanding disease pathogenesis but also for discriminating clinical subgroups with markedly distinct course and outcome. Of utmost importance was the identification of quasi-identical BcR IGs among unrelated patients with CLL, fittingly coined as "stereotypy," that set the wheels in motion for unraveling the role of antigen(s) in the selection and expansion of the leukemic clones. The categorization of CLL clones into "subsets" according to shared BcR IG structural characteristics provided a compartmentalized view of this otherwise heterogeneous disease, which eventually led to defining strikingly homogeneous groups of patients in terms of: (i) functional properties of the clonal BcR IGs, e.g. BcR reactivity and signaling; (ii) clonal genetic landscape, e.g. genomic aberrations, gene expression/methylation profiles, microRNA signatures; and (iii) clinical course and outcome. The remarkable restriction of the CLL IG gene repertoire, resulting to a great degree from the high impact of BcR IG stereotypy, may also prompt speculations regarding CLL ontogenesis. Overall, the BcR IG molecule justifiably lies at the heart of CLL clinical research, holding the promise of subset-tailored therapies.

AB - Over the last decade, immunogenetic analysis of B-cell receptor immunoglobulins (BcR IGs) has proved to be a particularly fruitful field in chronic lymphocytic leukemia (CLL), not only for understanding disease pathogenesis but also for discriminating clinical subgroups with markedly distinct course and outcome. Of utmost importance was the identification of quasi-identical BcR IGs among unrelated patients with CLL, fittingly coined as "stereotypy," that set the wheels in motion for unraveling the role of antigen(s) in the selection and expansion of the leukemic clones. The categorization of CLL clones into "subsets" according to shared BcR IG structural characteristics provided a compartmentalized view of this otherwise heterogeneous disease, which eventually led to defining strikingly homogeneous groups of patients in terms of: (i) functional properties of the clonal BcR IGs, e.g. BcR reactivity and signaling; (ii) clonal genetic landscape, e.g. genomic aberrations, gene expression/methylation profiles, microRNA signatures; and (iii) clinical course and outcome. The remarkable restriction of the CLL IG gene repertoire, resulting to a great degree from the high impact of BcR IG stereotypy, may also prompt speculations regarding CLL ontogenesis. Overall, the BcR IG molecule justifiably lies at the heart of CLL clinical research, holding the promise of subset-tailored therapies.

KW - B-cell receptors

KW - BcR IG

KW - Chronic lymphocytic leukemia

UR - http://www.scopus.com/inward/record.url?scp=84921863493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921863493&partnerID=8YFLogxK

U2 - 10.3109/10428194.2013.879715

DO - 10.3109/10428194.2013.879715

M3 - Article

VL - 55

SP - 2252

EP - 2261

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 10

ER -